Chondroitin Sulfate Synthase 1 Enhances Proliferation of Glioblastoma by Modulating PDGFRA Stability

Overview

Journal Oncogenesis

Date 2020 Feb 6

PMID 32019907

Citations 12

Authors

Wen-Chieh Liao

Chih-Kai Liao

To-Jung Tseng

Ying-Jui Ho

Ying-Ru Chen

Kuan-Hung Lin

Te-Jen Lai

Chyn-Tair Lan

Kuo-Chen Wei

Chiung-Hui Liu

Affiliations

Soon will be listed here.

Abstract

Chondroitin sulfate synthases, a family of enzyme involved in chondroitin sulfate (CS) polymerization, are dysregulated in various human malignancies, but their roles in glioma remain unclear. We performed database analysis and immunohistochemistry on human glioma tissue, to demonstrate that the expression of CHSY1 was frequently upregulated in glioma, and that it was associated with adverse clinicopathologic features, including high tumor grade and poor survival. Using a chondroitin sulfate-specific antibody, we showed that the expression of CHSY1 was significantly associated with CS formation in glioma tissue and cells. In addition, overexpression of CHSY1 in glioma cells enhanced cell viability and orthotopic tumor growth, whereas CHSY1 silencing suppressed malignant growth. Mechanistic investigations revealed that CHSY1 selectively regulates PDGFRA activation and PDGF-induced signaling in glioma cells by stabilizing PDGFRA protein levels. Inhibiting PDGFR activity with crenolanib decreased CHSY1-induced malignant characteristics of GL261 cells and prolonged survival in an orthotopic mouse model of glioma, which underlines the critical role of PDGFRA in mediating the effects of CHSY1. Taken together, these results provide information on CHSY1 expression and its role in glioma progression, and highlight novel insights into the significance of CHSY1 in PDGFRA signaling. Thus, our findings point to new molecular targets for glioma treatment.

Citing Articles

Metabolic gatekeepers: harnessing tumor-derived metabolites to optimize T cell-based immunotherapy efficacy in the tumor microenvironment.

Zheng Y, Xu R, Chen X, Lu Y, Zheng J, Lin Y Cell Death Dis. 2024; 15(10):775.

PMID: 39461979 PMC: 11513100. DOI: 10.1038/s41419-024-07122-6.

The prognostic implications and tumor-promoting functions of CHSY3 in gastric cancer.

Wang H, Zhang J, Wei Z, Chen S, Zheng J, Li Y Front Immunol. 2024; 15:1364979.

PMID: 38812506 PMC: 11133601. DOI: 10.3389/fimmu.2024.1364979.

CHST11-modified chondroitin 4-sulfate as a potential therapeutic target for glioblastoma.

Lin Y, Chu Y, Liao W, Chen C, Hsiao W, Ho Y Am J Cancer Res. 2023; 13(7):2998-3012.

PMID: 37559985 PMC: 10408464.

Targeting Chondroitin Sulphate Synthase 1 (Chsy1) Promotes Axon Growth Following Neurorrhaphy by Suppressing Versican Accumulation.

Liu C, Ho Y, Wang C, Hsu C, Chu Y, Hsu M Molecules. 2023; 28(9).

PMID: 37175152 PMC: 10180239. DOI: 10.3390/molecules28093742.

Glioblastoma: Current Status, Emerging Targets, and Recent Advances.

Thakur A, Faujdar C, Sharma R, Sharma S, Malik B, Nepali K J Med Chem. 2022; 65(13):8596-8685.

PMID: 35786935 PMC: 9297300. DOI: 10.1021/acs.jmedchem.1c01946.

References

Munkley J, Elliott D . Hallmarks of glycosylation in cancer. Oncotarget. 2016; 7(23):35478-89. PMC: 5085245. DOI: 10.18632/oncotarget.8155. View

Djerbal L, Lortat-Jacob H, Kwok J . Chondroitin sulfates and their binding molecules in the central nervous system. Glycoconj J. 2017; 34(3):363-376. PMC: 5487772. DOI: 10.1007/s10719-017-9761-z. View

Kwok J, Warren P, Fawcett J . Chondroitin sulfate: a key molecule in the brain matrix. Int J Biochem Cell Biol. 2012; 44(4):582-6. DOI: 10.1016/j.biocel.2012.01.004. View

Keough M, Rogers J, Zhang P, Jensen S, Stephenson E, Chen T . An inhibitor of chondroitin sulfate proteoglycan synthesis promotes central nervous system remyelination. Nat Commun. 2016; 7:11312. PMC: 4853428. DOI: 10.1038/ncomms11312. View

Bradbury E, Moon L, Popat R, King V, Bennett G, Patel P . Chondroitinase ABC promotes functional recovery after spinal cord injury. Nature. 2002; 416(6881):636-40. DOI: 10.1038/416636a. View

Wade A, Robinson A, Engler J, Petritsch C, James C, Phillips J . Proteoglycans and their roles in brain cancer. FEBS J. 2013; 280(10):2399-417. PMC: 3644380. DOI: 10.1111/febs.12109. View

Wang J, Svendsen A, Kmiecik J, Immervoll H, Skaftnesmo K, Planaguma J . Targeting the NG2/CSPG4 proteoglycan retards tumour growth and angiogenesis in preclinical models of GBM and melanoma. PLoS One. 2011; 6(7):e23062. PMC: 3146530. DOI: 10.1371/journal.pone.0023062. View

Svendsen A, Verhoeff J, Immervoll H, Brogger J, Kmiecik J, Poli A . Expression of the progenitor marker NG2/CSPG4 predicts poor survival and resistance to ionising radiation in glioblastoma. Acta Neuropathol. 2011; 122(4):495-510. PMC: 3185228. DOI: 10.1007/s00401-011-0867-2. View

Stallcup W . NG2 Proteoglycan Enhances Brain Tumor Progression by Promoting Beta-1 Integrin Activation in both Cis and Trans Orientations. Cancers (Basel). 2017; 9(4). PMC: 5406706. DOI: 10.3390/cancers9040031. View

10.

Su G, Meyer K, Nandini C, Qiao D, Salamat S, Friedl A . Glypican-1 is frequently overexpressed in human gliomas and enhances FGF-2 signaling in glioma cells. Am J Pathol. 2006; 168(6):2014-26. PMC: 1606624. DOI: 10.2353/ajpath.2006.050800. View

11.

Jijiwa M, Demir H, Gupta S, Leung C, Joshi K, Orozco N . CD44v6 regulates growth of brain tumor stem cells partially through the AKT-mediated pathway. PLoS One. 2011; 6(9):e24217. PMC: 3167830. DOI: 10.1371/journal.pone.0024217. View

12.

Zhou Z, Wang J, Cao R, Morita H, Soininen R, Chan K . Impaired angiogenesis, delayed wound healing and retarded tumor growth in perlecan heparan sulfate-deficient mice. Cancer Res. 2004; 64(14):4699-702. DOI: 10.1158/0008-5472.CAN-04-0810. View

13.

Kazanskaya G, Tsidulko A, Volkov A, Kiselev R, Suhovskih A, Kobozev V . Heparan sulfate accumulation and perlecan/HSPG2 up-regulation in tumour tissue predict low relapse-free survival for patients with glioblastoma. Histochem Cell Biol. 2018; 149(3):235-244. DOI: 10.1007/s00418-018-1631-7. View

14.

Oyinlade O, Wei S, Lal B, Laterra J, Zhu H, Goodwin C . Targeting UDP-α-D-glucose 6-dehydrogenase inhibits glioblastoma growth and migration. Oncogene. 2018; 37(20):2615-2629. PMC: 5957772. DOI: 10.1038/s41388-018-0138-y. View

15.

Phillips J, Huillard E, Robinson A, Ward A, Lum D, Polley M . Heparan sulfate sulfatase SULF2 regulates PDGFRα signaling and growth in human and mouse malignant glioma. J Clin Invest. 2012; 122(3):911-22. PMC: 3287216. DOI: 10.1172/JCI58215. View

16.

Liao W, Liao C, Tsai Y, Tseng T, Chuang L, Lan C . DSE promotes aggressive glioma cell phenotypes by enhancing HB-EGF/ErbB signaling. PLoS One. 2018; 13(6):e0198364. PMC: 5986151. DOI: 10.1371/journal.pone.0198364. View

17.

Sugahara K, Mikami T . Chondroitin/dermatan sulfate in the central nervous system. Curr Opin Struct Biol. 2007; 17(5):536-45. DOI: 10.1016/j.sbi.2007.08.015. View

18.

Ekstrand A, James C, Cavenee W, Seliger B, Pettersson R, Collins V . Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res. 1991; 51(8):2164-72. View

19.

Brennan C, Verhaak R, McKenna A, Campos B, Noushmehr H, Salama S . The somatic genomic landscape of glioblastoma. Cell. 2013; 155(2):462-77. PMC: 3910500. DOI: 10.1016/j.cell.2013.09.034. View

20.

Mizumoto S, Yamada S, Sugahara K . Molecular interactions between chondroitin-dermatan sulfate and growth factors/receptors/matrix proteins. Curr Opin Struct Biol. 2015; 34:35-42. DOI: 10.1016/j.sbi.2015.06.004. View